Receptor News and Research

RSS

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.

18 Sep 2010

Research on signaling pathways may help to design therapy for neurodevelopmental disorders

Researchers at the Center for Neuroscience Research at Children's National Medical Center have discovered that the two major types of signaling pathways activated during brain cell development-the epidermal growth factor receptor pathway and the Notch pathway-operate together to determine how many and which types of brain cells are created during growth and repair in developing and adult brains.

17 Sep 2010

Researchers target specific molecule in brain to prevent relapses in cocaine addicts

People who have used cocaine run a great risk of becoming addicted, even after long drug-free periods. Now researchers at Linköping University and their colleagues can point to a specific molecule in the brain as a possible target for treatment to prevent relapses.

16 Sep 2010

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.

16 Sep 2010

Study finds GRK2 molecule promotes cell death after heart attack

A molecule known to be involved in progressive heart failure has now been shown to also lead to permanent damage after a heart attack, according to researchers at Thomas Jefferson University.

16 Sep 2010

Consuming alcohol after diagnosis increases breast cancer recurrence risk: Study

In the Life After Cancer Epidemiology (LACE) study, 1,897 participants diagnosed with early-stage breast cancer between 1997 and 2000 and recruited on average 2 years post-breast cancer diagnosis were evaluated for the association between alcohol intake and breast cancer recurrence and death.

16 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

AMRI selects compound for advanced preclinical testing in treatment of IBS

AMRI today announced the selection of a compound from its proprietary research program for the treatment of irritable bowel syndrome (IBS) for advanced preclinical testing, with the goal of submitting an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in 2011.

15 Sep 2010

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.

15 Sep 2010

Mechanism linking brain activity to sleep discovered

Washington State University researchers have discovered the mechanism by which the brain switches from a wakeful to a sleeping state. The finding clears the way for a suite of discoveries, from sleeping aids to treatments for stroke and other brain injuries.

15 Sep 2010

Structural component inside neurons dances when connections are strengthened

Scientists at Emory University School of Medicine have uncovered how a structural component inside neurons performs two coordinated dance moves when the connections between neurons are strengthened.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Trevena Inc., the leader in the discovery and development of G-protein coupled receptor biased ligands, today announced that its scientists are presenting two posters featuring compelling preclinical pharmacology data on TRV120027 at the 14th Annual Heart Failure Society of America Meeting being held September 12-15, 2010 in San Diego.

13 Sep 2010

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

13 Sep 2010

Shire announces expansion of Human Genetic Therapies pipeline

Shire plc, the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.

10 Sep 2010

Discovery on Mycobacterium tuberculosis can offer new approaches for TB prevention

One third of the world's population is infected with Mycobacterium tuberculosis (MTB), which leads to tuberculosis (TB), a leading cause of death world-wide. A new discovery, led by a team of researchers from Case Western Reserve University School of Medicine, offers hope for new approaches to the prevention and treatment of TB. The team's discovery of a novel mechanism that may contribute to immune recognition of MTB is published in the September issue of Nature Structural and Molecular Biology.

10 Sep 2010

Seaside reports positive data from STX209 Phase 2 study in ASD

Seaside Therapeutics, Inc. announced today positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD). The primary endpoint of the study, an improvement on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I), achieved statistical significance (p<0.001).

9 Sep 2010

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.

9 Sep 2010

Anchor Therapeutics collaborates with OMJPI to develop GPCR targeted therapeutic compounds

Anchor Therapeutics today announced that it has entered into a collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. with the goal of developing G protein coupled receptor (GPCR) targeted therapeutic compounds utilizing Anchor's proprietary pepducin technology.

9 Sep 2010

Scientists identify molecular marker to analyze chemotherapy response in breast cancer patients

A new predictive marker which could help doctors to decide whether breast cancer patients would benefit from chemotherapy has been identified by a team of scientists. The study, part-funded by Cancer Research UK and published in the British Journal of Cancer today (Wednesday), shows for the first time how this molecular marker has been singled out as an independent factor in examining a breast cancer patient's tumour.

9 Sep 2010

Receptor News and Research

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Research on signaling pathways may help to design therapy for neurodevelopmental disorders

Researchers target specific molecule in brain to prevent relapses in cocaine addicts

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Study finds GRK2 molecule promotes cell death after heart attack

Consuming alcohol after diagnosis increases breast cancer recurrence risk: Study

Phase II clinical trial shows GTx-758 reduces serum free testosterone

AMRI selects compound for advanced preclinical testing in treatment of IBS

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Mechanism linking brain activity to sleep discovered

Structural component inside neurons dances when connections are strengthened

Study finds new therapeutic target for polycystic kidney disease

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

Shire announces expansion of Human Genetic Therapies pipeline

Discovery on Mycobacterium tuberculosis can offer new approaches for TB prevention

Seaside reports positive data from STX209 Phase 2 study in ASD

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Anchor Therapeutics collaborates with OMJPI to develop GPCR targeted therapeutic compounds

Scientists identify molecular marker to analyze chemotherapy response in breast cancer patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News